<?xml version="1.0" encoding="UTF-8"?>
<p>According to the NTP report (NTP, 
 <xref rid="efs26548-bib-0060" ref-type="ref">2011</xref>) on 2‐year gavage studies with rats (dose levels 12.5, 25 and 50 mg/kg) and mice (dose levels 3, 6, 12, 25 mg/kg), ‘there was some evidence of carcinogenic activity of α,β‐thujone in male F344/N rats based on increased incidences of preputial gland neoplasms at the dose level of 25 mg/kg (all rats at 50 mg/kg died before the end of the study);
 <xref ref-type="fn" rid="efs26548-note-1030">28</xref> increased incidences of benign pheochromocytoma of the adrenal medulla may have been related to administration of α,β‐thujone in male F344/N rats administered 12.5 or 25 mg/kg.
 <xref ref-type="fn" rid="efs26548-note-1031">29</xref> There was no evidence of carcinogenic activity of α,β‐thujone in female F344/N rats administered 12.5 or 25 mg/kg. There was no evidence of carcinogenic activity of α,β‐thujone in male or female B6C3F1 mice administered 3, 6, or 12 mg/kg.’
</p>
